Starpharma Holdings ROE 2024

Starpharma Holdings Aktienanalyse

What does Starpharma Holdings do?

Starpharma Holdings Ltd is an Australian company specializing in the development of innovative solutions in the fields of pharmacy and biotechnology. The company was founded in 1996 and has since written an impressive history full of successful developments and numerous partnerships. The main business of Starpharma focuses on the development and commercialization of drugs and other health products based on dendrimer technology. One of the most advanced applications of dendrimer technology is VivaGel, a topical gel for the prevention of sexually transmitted diseases, particularly HPV (Human Papillomavirus). VivaGel is based on a dendrimer that acts both as an antiviral agent and an antibiotic, capable of preventing infection by different types of HPV. The product has already undergone Phase III clinical trials and is currently being marketed worldwide. In addition to VivaGel, Starpharma also offers dendrimer-based technologies and services in the field of drug development. The company has formed numerous partnerships with major pharmaceutical companies such as AstraZeneca, GSK, and Merck, and is involved in the development of drugs for cancer, autoimmune diseases, and infectious diseases. Furthermore, Starpharma has expanded its dendrimer technology to other industries, such as agriculture, where dendrimers can contribute to improving soil quality and reducing pesticide use. In this sector, Starpharma has also formed partnerships with agricultural companies such as Adama and Nufarm. Overall, Starpharma is a company that has experienced significant growth in recent years and continues to focus on the development of new and innovative products and solutions. Its core competence in dendrimer technology has allowed it to establish itself as a key player in various industries and build numerous partnerships with global companies. With its diverse range of products and services and a strong focus on research and development, Starpharma can be considered an important player in the field of biotechnology and healthcare innovations. Indicate the sector in starpharma specialize in. Starpharma Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Starpharma Holdings's Return on Equity (ROE)

Starpharma Holdings's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Starpharma Holdings's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Starpharma Holdings's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Starpharma Holdings’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Starpharma Holdings Stock

What is the ROE (Return on Equity) of Starpharma Holdings this year?

The ROE of Starpharma Holdings this year is -0.45 undefined.

How has the Return on Equity (ROE) of Starpharma Holdings developed compared to the previous year?

The ROE of Starpharma Holdings has increased by 34.56% increased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Starpharma Holdings?

A high ROE indicates that Starpharma Holdings generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Starpharma Holdings?

A low ROE can indicate that Starpharma Holdings is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Starpharma Holdings affect the company?

A change in ROE (Return on Equity) of Starpharma Holdings can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Starpharma Holdings?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Starpharma Holdings?

Some factors that can influence Starpharma Holdings's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Starpharma Holdings pay?

Over the past 12 months, Starpharma Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Starpharma Holdings is expected to pay a dividend of 0 AUD.

What is the dividend yield of Starpharma Holdings?

The current dividend yield of Starpharma Holdings is .

When does Starpharma Holdings pay dividends?

Starpharma Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Starpharma Holdings?

Starpharma Holdings paid dividends every year for the past 0 years.

What is the dividend of Starpharma Holdings?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Starpharma Holdings located?

Starpharma Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Starpharma Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Starpharma Holdings from 6/27/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 6/27/2024.

When did Starpharma Holdings pay the last dividend?

The last dividend was paid out on 6/27/2024.

What was the dividend of Starpharma Holdings in the year 2023?

In the year 2023, Starpharma Holdings distributed 0 AUD as dividends.

In which currency does Starpharma Holdings pay out the dividend?

The dividends of Starpharma Holdings are distributed in AUD.